Physician profile
Jonathan C Koning
NPI 1710216841
$47,006.22
in general payments reported to CMS, 2019-2025
58 companies · $7,640 in 2025
The $7,640 reported for 2025 was more than what 94% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,322 · 2020: $8,682 · 2021: $7,095 · 2022: $2,909 · 2023: $2,005 · 2024: $13K · 2025: $7,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $7,442 · Travel and Lodging: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,675.00 |
| Food and Beverage | $7,441.64 |
| Travel and Lodging | $881.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20,693.82 | 2021-2025 | Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $10,016.05 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $2,884.58 | 2020 | |
| Collegium Pharmaceutical, INC. | $1,683.11 | 2019-2025 | Xtampza |
| Abbvie INC. | $1,637.75 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $817.78 | 2021-2025 | Relistor |
| Daiichi Sankyo INC. | $795.80 | 2019 | |
| Amgen INC. | $745.22 | 2019-2023 | Aimovig |
| Pfizer INC. | $729.40 | 2019-2025 | |
| Abbott Laboratories | $701.98 | 2019-2025 | Eterna, Octrode |
| Mdd US Operations, LLC | $587.17 | 2019-2020 | |
| Tersera Therapeutics LLC | $540.88 | 2019-2025 | Prialt |
| Uswm, LLC | $496.54 | 2021-2023 | Zimhi, Lucemyra |
| Vertiflex, INC. | $444.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $429.50 | 2019-2023 | Ajovy |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Koning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.